{"count": 2, "results": [{"_id": "37158620", "pmid": 37158620, "title": "A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.", "journal": "Pediatr Blood Cancer", "authors": ["Cash T", "Jonus HC", "Tsvetkova M", "Beumer JH", "Sadanand A", "Lee JY", "Henry CJ", "Aguilera D", "Harvey RD", "Goldsmith KC"], "date": "2023-08-01T00:00:00Z", "doi": "10.1002/pbc.30405", "meta_date_publication": "2023 Aug", "meta_volume": "70", "meta_issue": "8", "meta_pages": "e30405", "score": 50245.453, "text_hl": "We conducted a phase 1 trial to determine the maximum tolerated dose (MTD) of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ with @CHEMICAL_Topotecan @CHEMICAL_MESH:D019772 @@@topotecan@@@ and @CHEMICAL_Cyclophosphamide @CHEMICAL_MESH:D003520 @@@cyclophosphamide@@@ in children with relapsed/refractory @<m>DISEASE_Central_Nervous_System_Neoplasms</m> @DISEASE_MESH:D016543 @@@solid and central nervous system (CNS) tumors@@@. ", "citations": {"NLM": "Cash T, Jonus HC, Tsvetkova M, Beumer JH, Sadanand A, Lee JY, Henry CJ, Aguilera D, Harvey RD, Goldsmith KC. A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors. Pediatr Blood Cancer. 2023 Aug;70(8):e30405. PMID: 37158620", "BibTeX": "@article{37158620, title={A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.}, author={Cash T and Jonus HC and Tsvetkova M and Beumer JH and Sadanand A and Lee JY and Henry CJ and Aguilera D and Harvey RD and Goldsmith KC}, journal={Pediatr Blood Cancer}, volume={70}, number={8}, pages={e30405}}"}}, {"_id": "24269626", "pmid": 24269626, "title": "Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data.", "journal": "Eur J Pharm Sci", "authors": ["Jacus MO", "Throm SL", "Turner DC", "Patel YT", "Freeman BB 3rd", "Morfouace M", "Boulos N", "Stewart CF"], "date": "2014-06-16T00:00:00Z", "doi": "10.1016/j.ejps.2013.11.010", "meta_date_publication": "2014 Jun 16", "meta_volume": "57", "meta_issue": "", "meta_pages": "41-7", "score": 50068.902, "text_hl": "Here, we also present how our approach was used to examine two FDA approved drugs, @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ and @CHEMICAL_Pemetrexed @CHEMICAL_MESH:D000068437 @@@pemetrexed@@@, as candidates for new therapies for pediatric @<m>DISEASE_Central_Nervous_System_Neoplasms</m> @DISEASE_MESH:D016543 @@@CNS tumors@@@. ", "citations": {"NLM": "Jacus MO, Throm SL, Turner DC, Patel YT, Freeman BB 3rd, Morfouace M, Boulos N, Stewart CF. Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data. Eur J Pharm Sci. 2014 Jun 16;57():41-7. PMID: 24269626", "BibTeX": "@article{24269626, title={Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data.}, author={Jacus MO and Throm SL and Turner DC and Patel YT and Freeman BB 3rd and Morfouace M and Boulos N and Stewart CF}, journal={Eur J Pharm Sci}, volume={57}, pages={41-7}}"}}]}